Bronchogen Dosage, half-life & reference guide

Also known as Ala-Glu-Asp-Leu · AEDL peptide

Reviewed Evidence: EmergingPublished by PepVault

A four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the airways and lungs. In rats with a COPD-like lung disease, a month of it restored the airway lining and calmed inflammation; in the lab it binds DNA. No human study has been published.

How often
Daily
Half-life
Unknown
Evidence
●●● Emerging
Routes
SubQ, Oral capsules

No human study has tested a dose of Bronchogen: the amounts people run are their own protocol, not a reference.

How it works.

A tetrapeptide, Ala-Glu-Asp-Leu (AEDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers describe as the bioregulator of the bronchi and lungs. In rats given a lung disease like COPD by two months of nitrogen dioxide, a month of Bronchogen restored the airway lining, raised the local immune antibody secretory IgA and the surfactant protein that keeps air sacs open, and calmed neutrophil inflammation, in studies by a St. Petersburg lung research group. In the lab it binds DNA and raised the temperature at which DNA strands separate, which its developers read as a sign it acts on genes. No human study of Bronchogen is indexed on PubMed.

Commonly reported: Little to feel; user reports are few.

A smiling woman with silver hair in a grey training top by a window, holding her phone

PepVault for iPhone

Track bronchogen in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Bronchogen works.

A body with Immune system lit
  • Immune system

    In animals. Raised the local immune antibody secretory IgA and the surfactant protein that keeps air sacs open, and calmed neutrophil inflammation.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Not established (no human data)
Peak effect
Not established
Duration
Courses of about 10 days (community practice)
  1. Day 1–10Community

    No human data to set expectations

    Bronchogen has never been studied in people, so any change you notice is yours to judge. Commonly reported: little to feel; some redness or itch where it goes in. A line each day on breathing and energy gives you something honest to compare.

    Updated Nov 2026

  2. Day 10–30Animal

    What the rat studies measured

    In rats with a COPD-like lung disease, a month of Bronchogen restored the airway lining and calmed inflammation in the airways. That is a rat model, and no study has tested it in people with lung disease.

    The science

    Kuzubova 2015: COPD modelled in rats by 60 days of intermittent NO2; a month of Bronchogen removed goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, restored ciliated cells and raised secretory IgA. Titova 2017: in the same model, lower neutrophilic inflammation, normalized cytokines and enzymes in lavage fluid, more secretory IgA and surfactant protein B.

    Sources
    • Kuzubova et al. (2015)
    • Titova et al. (2017)

    Updated Nov 2026

  3. Any dayAnimal

    What Bronchogen is built on

    A four-amino-acid peptide from the Russian bioregulator program, its peptide for the lungs. Its evidence is two rat studies of a COPD-like disease and lab studies of how it binds DNA; there is no human study.

    The science

    Khavinson 2021 review (Table 5): AEDL, Bronchogen, regulation of lung cells. Kuzubova 2015 and Titova 2017: rat NO2 model of COPD (a St. Petersburg pulmonology group). Monaselidze 2011: raised DNA melting temperature by 3.1 °C, not specific to A-T or G-C pairs. Fedoreyeva 2011: preferential binding to CTG-containing sequences.

    Sources
    • Khavinson et al. (2021)
    • Kuzubova et al. (2015)
    • Titova et al. (2017)
    • Monaselidze et al. (2011)
    • Fedoreyeva et al. (2011)

    Updated Nov 2026

  4. With ThymalinCommunity

    With the thymus extract

    Bronchogen is sometimes run beside other bioregulators, one per organ. If one of them is Thymalin: its own Russian study reported fewer respiratory infections in older adults. No study has given the two together.

    The science

    Khavinson and Morozov 2003: in 266 older adults followed 6–8 years, acute respiratory infections were 2.0–2.4 times less common with the thymus and pineal extracts than in a control group. Running bioregulators side by side is community practice; this pair has no study.

    Sources
    • Khavinson et al. (2003)

    Updated Nov 2026

Day 1 is the day you start it.

No human study of Bronchogen has been published. The effects come from rat studies by a St. Petersburg lung research group and from lab studies of DNA by its developers.

Preliminary research

A typical run.

Run notes

Cycle
Run in short courses rather than continuously, like the other bioregulators: community courses run about 10 days, a few times a year. The rat studies gave it for a month. No study in people has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
Timing
No timing has been studied.
Routes
SubQ injection, Oral capsules
Stacks
Thymalin

Track it in the app

Safety.

Common side effects

  • Injection-site redness or itch

Interactions

No interaction studies exist, including with inhaled medicines for asthma or COPD.

Safety notes

No safety study exists: no human study of Bronchogen is indexed, so nothing is known about its side effects beyond user reports, or about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, or with asthma, COPD or another lung condition, which need their own treatment.

Goes with.

Questions people ask.

What is Bronchogen?

A four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the airways and lungs. In rats with a COPD-like lung disease, a month of it restored the airway lining and calmed inflammation; in the lab it binds DNA. No human study has been published.

How is Bronchogen dosed in research?

The library carries no reference dose for Bronchogen. No human study has tested a dose of Bronchogen: the amounts people run are their own protocol, not a reference.

How long does Bronchogen last?

The half-life of Bronchogen is unknown (never measured).

What do people report on Bronchogen?

Commonly reported on Bronchogen: little to feel; user reports are few.

Is Bronchogen safe?

The research basis for Bronchogen is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site redness or itch.

What does Bronchogen stack with?

Common stacks for Bronchogen: Thymalin.

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Daily

Half-life

Unknown

Unknown (never measured)

Research basis

●●● Emerging

Primarily preclinical / limited human data

PepVault for iPhone

Track bronchogen in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library